Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... MALVERN, Pa. , April 27, 2015 /PRNewswire/ ... development and commercialization of products focused on the ... executive team of William Stewart and ... mark important steps in SCILEX,s proprietary drug development ... of its products. The Company,s first product, ZTlido™ ...
(Date:4/27/2015)... 27, 2015 Harwood Feffer LLP ( www.hfesq.com ... directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") ... breached its fiduciary duties to shareholders. On ... announcing results from its first Phase 3 registration trial ... that in the trial, Rhopressa failed to meet its ...
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
Breaking Medicine Technology:SCILEX Pharmaceuticals Announces Commercial Executive Appointments 2SCILEX Pharmaceuticals Announces Commercial Executive Appointments 3Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2
... March 06, 2007 /PRNewswire/ -- Up to two ... up to 600,000,hospitalized. Its primary complication, pulmonary embolism ... than breast cancer and,AIDS combined. People who suffer ... DVT, because these factors also heighten the,likelihood of ...
... POZEN Inc.,(NASDAQ: POZN), today announced top-line results of its ... of 2006. PA 325 is a patented formulation of ... immediate release,formulation of a proton pump inhibitor., The PA ... subjects,over the age of 50. Each subject was treated ...
Cached Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 3
(Date:4/27/2015)... 27, 2015 Array Health , ... has announced that Lance Hood, senior director of marketing, ... annual Direct-to-Consumer Health Care Marketing Summit on ... Smith, Partner and Director of Payer Services, Leavitt Partners, ... consumerism – through a retail/e-commerce perspective – and equip ...
(Date:4/27/2015)... 27, 2015 Beckman Coulter is sponsoring ... to study the evolution of neural circuitry and swimming ... review the mechanisms by which analogous forms of swimming ... flexions, evolved independently in certain sea slug clades. The ... live April 30, 2015 at 8:00am PT. , Sea ...
(Date:4/27/2015)... Los Angeles, CA (PRWEB) April 27, 2015 ... years has been to connect clients of personal injury attorneys ... The network of doctors has seen steady growth throughout their ... Dr. Charles E. Richardson, DC and his team in ... team including a medical doctor and massage therapist, patients can ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... 27, 2015 Douglas Fitzpatrick not ... clients feel secure, but also helps secure homes for animals. ... Douglas will be manning a booth at the 2015 Fetch ... 717 E. 17th Ave., Columbus, Ohio. , “I am ... will feature hundreds of adoptable pets from more than forty ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2
... prevalence of leprosy is decreasing to about 0.95 cases per ... is eliminated from India. // But this statement is very ... completely eliminated but the prevalence is significantly reduced. It is ... 10,000 population. ,In India Delhi has a high ...
... feel good when they are complimented on their age. It is ... // life with loads of money minus the worries. It is ... and drink heavily. ,This study mainly aims in understanding ... on the way men and women age. It is very astonishing ...
... number of dentists who graduate from the dental schools stay in ... rise and the health officials fear that his is due to ... ,Many dental graduates are out of job due to this ... the dental graduates who left Scotland to find work elsewhere but ...
... that consumption of fish oil can counteract the effect of ... health. // The results of the present study have valuable ... ,The study participants were required to consume a ... months. Those who consumed soy oil supplements formed the control ...
... potential of stem cells in the repair and treatment ... stem cells from muscle tissue // of injured rats ... a therapeutic protein (bone morphogenetic protein 4, BMP-4, capable ... a repair mechanism can be instituted in humans as ...
... based Vancouver Company Copeman Healthcare Inc.’s may face charges ... to charge an initial consultation fee of $3,500. // ... memorandum to the Health ministry to take action against ... based treatment and recommends universal rate for all treatment. ...
Cached Medicine News:Health News:Lifestyle plays an important role in determining one’s ag 2Health News:Shortage of dentists in Scotland 2Health News:Muscle Derived Stem Cell Can Repair Damaged Cartilage 2
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
Agility has delivered a RFID-enabled mobile asset management program....
Agility can provide tracking and management of surgical instruments, instrument trays and case carts to significantly enhance the current central sterile department flow by improving efficiency....
Assetrac allows identification, location, and protection of your assets....
Medicine Products: